Saturday 17 October 2026 Export HUM’s income statement to Excel — free account

Humana Inc.

Humana Inc.’s revenue for fiscal 2025 (year ended December 2025) was $129.7 billion, up 10.1% from fiscal 2024. In the quarter to June 2026, revenue grew 26.2%, EPS grew 27.9%, free cash flow grew 58.5% and total debt rose 13.2%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for five; insiders bought in the last twelve months.

413.16 19.04 −4.41%

Follow HUM

Alert me

Market cap: $51.9B
P/E: 38.8×
Fwd P/E: 42.9×
Dividend yield: 0.86%
F-score: 6/9
Altman Z: 4.66
Beneish M: −2.29
Dividend safety: 61/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Insider Decisions trades per month

Total buys 0.15

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	1	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.26%

Capital & Financial Ratios $m

Market Cap 51,900.00

Revenue 145,679.00

Net Income 1,295.00

Free Cash Flow 1,972.00

Net Debt (9,624.00)

Current Ratio 1.74

Debt/Equity 0.74

P/E ratio 38.79

Fwd P/E 42.90

P/S ratio 0.34

P/B ratio 2.57

Past 5Y EPS Growth (17.22%)

This Y EPS Growth (46.56%)

Next Y EPS Growth 85.17%

Next Y revenue growth (87.46%)

Next 5Y EPS Growth 21.20%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 97.27%

10-year low 10-year high

P/S against its own 10 years 19.20%

10-year low 10-year high

P/B against its own 10 years 27.61%

10-year low 10-year high

EV/Sales against its own 10 years 20.13%

10-year low 10-year high

EV/FCF against its own 10 years 73.52%

10-year low 10-year high

Dividends

Payout Ratio 0.33

Annual Dividend Rate 3.54

Annual Dividend Yield 0.86%

	total	individual payouts
2028	Powerpack
2027	Powerpack
2026	0.37	0.89 0.89 0.89
2025	0.40	0.89 0.89 0.89 0.89
2024	3.54	0.89 0.89 0.89 0.89
2023	3.54	0.89 0.89 0.89 0.89
2022	3.15	0.79 0.79 0.79 0.79
2021	2.80	0.70 0.70 0.70 0.70
2020	2.50	0.63 0.63 0.63 0.63
2019	2.20	0.55 0.55 0.55 0.55
2018	2.00	0.50 0.50 0.50 0.50
2017	1.89	0.29 0.40 0.40 0.40 0.40
2016	0.87	0.29 0.29 0.29

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	21,320	20,435	19,903	23,871
Receivables	2,035	2,704	3,270	5,695
Inventory	—	—	—	—
Other	6,631	6,676	9,560	10,520
	29,986	29,815	32,733	40,086

	2023	2024	2025	Q'26
Payables	6,569	5,259	5,717	7,263
ST’ Debt	1,443	577	—	2,268
Other	—	—	—	—
	18,872	16,939	16,346	23,007

Compound Annual Growth %

	10y	5y	3y
Sales	9.10%	10.94%	11.77%
Cash Flow	0.59%	(30.40%)	(41.44%)
Earnings	(0.71%)	(18.81%)	(24.91%)
Book Value	5.54%	5.26%	4.89%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	39,648	40,867	—	—	—
’25	32,112	32,388	32,649	32,515	129,664
’24	29,611	29,540	29,397	29,213	117,761
’23	26,742	26,747	26,423	26,462	106,374
’22	23,970	23,662	22,799	22,439	92,870
’21	20,668	20,645	20,697	21,054	83,064
’20	18,935	19,083	20,075	19,062	77,155

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	1,254	1,966	—	—	—
’25	331	1,271	971	(1,652)	921
’24	423	1,213	1,858	(528)	2,966
’23	6,687	3,176	1,252	(7,134)	3,981
’22	302	959	8,453	(5,127)	4,587
’21	(837)	360	2,835	(96)	2,262
’20	474	3,067	1,815	283	5,639

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	1,133	1,834	—	—	—
’25	236	1,157	836	(1,831)	398
’24	246	1,099	1,728	(675)	2,398
’23	6,464	2,912	1,018	(7,207)	3,187
’22	7	680	8,165	(5,385)	3,467
’21	(1,127)	31	2,509	(467)	946
’20	282	2,841	1,565	(13)	4,675

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	9.83	5.73	—	—	—
’25	10.30	4.51	1.62	(6.61)	9.84
’24	6.11	5.62	3.98	(5.76)	9.98
’23	9.87	7.66	6.71	(4.42)	20.00
’22	7.29	5.48	9.39	(0.12)	22.08
’21	6.39	4.55	11.84	(0.11)	22.67
’20	3.56	13.75	10.05	(2.07)	25.31

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	150.00	186.25	248.01	225.65	208.25	370.22	351.20	423.29	213.31	206.87	Analyst estimates 2026–2028 Powerpack
	High	217.80	264.56	355.88	372.92	474.70	475.44	571.30	541.21	475.00	315.35
People
People	Employees	51,600	45,900	41,600	46,000	48,700	95,500	67,100	67,600	65,680	67,060
	Revenue/emp, $m	1.05	1.17	1.37	1.41	1.58	0.87	1.38	1.57	1.79	1.93
Income, $m
Income, $m	Revenue	54,379	53,767	56,912	64,888	77,155	83,064	92,870	106,374	117,761	129,664
	Gross margin, %	17.23	19.10	19.38	17.00	20.12	16.69	18.50	16.90	14.52	14.54
	EBT	1,552	4,020	2,063	3,456	4,600	3,354	3,568	3,383	1,721	1,555
	EBT margin, %	2.85	7.48	3.62	5.33	5.96	4.04	3.84	3.18	1.46	1.20
	Net income	614	2,448	1,683	2,707	3,367	2,934	2,802	2,484	1,214	1,203
	Depreciation	465	485	534	575	616	713	845	917	968	824
Per share, $
Per share, $	Revenue	364.04	372.11	413.95	484.04	583.63	645.47	734.62	858.78	976.69	1,076.46
	Earnings	4.11	16.94	12.24	20.20	25.47	22.79	22.20	20.09	10.01	9.87
	Cash flow	12.96	28.04	15.81	39.42	42.66	17.58	36.28	32.14	24.60	7.65
	Capex	(3.53)	(3.63)	(4.45)	(5.49)	(7.29)	(10.23)	(8.86)	(6.41)	(4.71)	(4.34)
	Free cash flow	9.43	24.41	11.35	33.93	35.36	7.35	27.42	25.73	19.89	3.30
	Book value	71.53	68.11	73.91	89.79	103.84	125.13	121.58	131.74	136.39	147.25
	Shares, m	149	144	137	134	132	129	126	124	121	120
Valuation, ×
Valuation, ×	P/E	49.65	14.99	23.41	18.16	16.11	20.35	22.60	23.59	25.40	26.03
	P/S	0.54	0.68	0.69	0.76	0.70	0.72	0.68	0.55	0.26	0.24
	P/B	2.76	3.69	3.88	4.08	3.95	3.71	4.12	3.57	1.86	1.74
	EV/Sales	0.41	0.51	0.58	0.61	0.57	0.67	0.60	0.46	0.19	0.18
	EV/FCF	15.71	7.85	21.20	8.75	9.34	58.78	16.00	15.24	9.12	60.04
Cash, $m
Cash, $m	Operating cash flow	1,936	4,051	2,173	5,284	5,639	2,262	4,587	3,981	2,966	921
	Capex	(527)	(524)	(612)	(736)	(964)	(1,316)	(1,120)	(794)	(568)	(523)
	Free cash flow	1,409	3,527	1,561	4,548	4,675	946	3,467	3,187	2,398	398
Balance, $m
Balance, $m	Working capital	8,368	7,996	6,871	8,959	10,247	9,562	9,005	11,114	12,876	16,387
	Total debt	4,092	4,920	6,069	5,666	6,660	12,494	11,126	11,656	11,721	12,369
	Net debt	(7,380)	(8,679)	(6,300)	(9,360)	(10,567)	(4,092)	(7,816)	(9,664)	(8,714)	(7,534)
	Shareholders’ equity	10,685	9,842	10,161	12,037	13,728	16,103	15,370	16,318	16,445	17,737
Returns, %
Returns, %	ROA	2.45	9.31	6.40	9.94	10.51	7.39	6.42	5.52	2.58	2.49
	ROIC	32.92	229.04	50.18	74.52	98.58	16.38	31.44	37.69	20.71	16.56
	ROE	5.84	23.85	16.83	24.39	26.14	19.66	17.83	15.71	7.37	6.95

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
UNH UnitedHealth Group Incorporated	$365.0B	25.8×	23.3×	−0.41% (below 0%: shrinking)	+61.50% (above 0%: growing)	−15.65% (below 0%: shrinking)	100.00%	5.82%	Compare
CVS CVS Health Corporation	$118.4B	24.1×	15.4×	+7.26% (above 0%: growing)	+187.65% (above 0%: growing)	+338.29% (above 0%: growing)	44.52%	4.43%	Compare
ELV Elevance Health, Inc.	$92.9B	19.0×	20.3×	+1.40% (above 0%: growing)	−13.08% (below 0%: shrinking)	−9.01% (below 0%: shrinking)	15.77%	4.56%	Compare
CI Cigna Group	$79.0B	12.5×	11.4×	+6.68% (above 0%: growing)	+10.16% (above 0%: growing)	+66.93% (above 0%: growing)	88.24%	3.73%	Compare
HUM Humana Inc.	$51.9B	38.8×	42.9×	+26.18% (above 0%: growing)	+27.88% (above 0%: growing)	+58.51% (above 0%: growing)	13.45%	3.33%
CNC Centene Corporation	$34.8B	— (loss-making)	24.8×	+9.92% (above 0%: growing)	n/m	+116.61% (above 0%: growing)	8.59%	2.24%	Compare
MOH Molina Healthcare, Inc	$11.1B	— (loss-making)	55.0×	−4.84% (below 0%: shrinking)	−74.95% (below 0%: shrinking)	+5.81% (above 0%: growing)	13.19%	1.33%	Compare
OSCR Oscar Health, Inc.	$10.3B	18.6×	29.7×	+70.40% (above 0%: growing)	n/m	+316.29% (above 0%: growing)	22.25%	7.96%	Compare
CLOV Clover Health Investments, Corp.	$2.5B	— (loss-making)	292×	+55.60% (above 0%: growing)	n/m	+406.43% (above 0%: growing)	20.59%	3.77%	Compare
Median of peers	$56.9B	19.0×	24.1×	+6.97%	+10.16%	+91.77%	21.42%	4.10%

All 12 Healthcare Plans stocks →

Humana Inc. (HUM) key facts

Concern: Net income was $1.2 billion, or $9.87 per share (basic), a net margin of 0.92%.
Strength: Humana Inc.’s revenue for fiscal 2025 (year ended December 2025) was $129.7 billion, up 10.1% from fiscal 2024.
Humana Inc. (HUM) is a Healthcare Plans company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, HUM traded at $413.16, a market capitalization of $51.9 billion.
At that price the stock trades at 38.8× trailing-twelve-month earnings and 0.3× sales; its P/E is higher than 97% of its own readings over the past ten years.
Humana Inc. pays an annual dividend of $3.54 per share, a yield of 0.86%, with a payout ratio of 33.5%.
Return on equity was 6.95% and debt-to-equity 0.74.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 4.66 (safe zone) for fiscal 2025.